Skip to main content

Table 1 Adverse events experienced by patients treated with antiviral schedule regimens

From: Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

 

SOF/LDV

SOF/DAK

SOF/SIM+/− RBV

SOF/RBV

OMB/PTR/r/DAS +/− RBV

ENROLLED PTS per regimen

20

15

28

4

11

PTS WITH SERIOUS ADRs

4 (20%)

3 (20%)

1 (4%)

1 (25%)

1 (9%)

DISCONTINUATION

3

0

0

0

1

DEATHS

0

0

0

0

0

COMMON ADRs

10 (50%)

6 (40%)

12 (43%)

4 (100%)

5 (45%)

FATIGUE

6

5

11

4

4

HEADACHE

0

0

0

0

0

NAUSEA

0

0

0

0

0

PRURITUS

0

0

4

0

0

INSOMNIA

1

3

0

0

0

DIARRHOEA

0

0

0

0

0

ASTHENIA

7

2

11

4

3

RASH

0

0

4

0

0

IRRITABILITY

0

4

0

0

0

ANAEMIA

6

3

12

3

3

DYSPNOEA

2

0

0

0

1

  1. *Common adverse drug reactions are not to single patients, one patient may experience more than one common adverse drug reaction. Data are expressed as absolute number plus percentage